DEF: Entera Bio Proposes Executive Compensation Hikes Amidst Soaring Shareholder Returns and Expanding Net Losses

Entera Bio Ltd. is seeking shareholder approval for significant executive compensation increases and an updated compensation policy, following a year of substantial shareholder return growth despite a widening net loss.

Summary

• Entera Bio Ltd. will hold its 2025 Annual Meeting of Shareholders on July 16, 2025, to vote on several key proposals, including director election, executive compensation, and an amended compensation policy.
• The company's share price saw a significant increase, with the value of a $100 investment on December 31, 2022, growing to $312 by December 31, 2024, reflecting a strong cumulative total shareholder return (TSR).
• Despite the positive TSR, the company's net loss increased from $8.889 million in fiscal year 2023 to $9.541 million in fiscal year 2024.
• Proposed compensation changes include a salary increase for CEO Miranda Toledano to $600,000 annually (from $419,000 in 2024), along with new option grants of 500,000 Ordinary Shares and RSU grants totaling 180,702 shares (136,842 in lieu of cash bonus and 43,860 in lieu of salary portion).
• Chief of Research & Development, Dr. Gregory Burshtein, is proposed to receive an annual gross base salary of $200,000 (from an implied $160,000) and new option grants of 200,000 Ordinary Shares, plus 26,316 RSUs in lieu of a 2024 cash bonus.
• Chief Financial Officer, Dana Yaacov-Garbeli, is proposed to receive an annual cash consideration of $251,983 (from $225,000) and new option grants of 130,000 Ordinary Shares, plus 26,316 RSUs in lieu of a 2024 cash bonus.
• The company is seeking approval for an amended and restated compensation policy that would increase the maximum annual value of equity awards granted to an Officer from 18 times to 25 times their monthly base salary, to align with market standards and attract talent.
• Shareholders will also vote on the re-election of Ms. Haya Taitel as a Class II director and the ratification of Kesselman & Kesselman (PwC) as the independent auditors for fiscal year 2025.

Sentiment

Score: 7

Explanation: The document presents a mixed financial picture with increasing net losses but strong share price performance and TSR in 2024. The proposed executive compensation increases, while significant, are justified by market benchmarks and are tied to long-term equity performance, which aligns management with shareholder interests. The overall sentiment is cautiously positive, leaning on the strong TSR and proactive governance measures for talent retention.

Positives

• The company demonstrated a strong cumulative Total Shareholder Return (TSR), with a $100 investment on December 31, 2022, growing to $312 by December 31, 2024, indicating significant share price appreciation.
• Executive compensation is increasingly tied to the company's share performance through equity awards, aligning management interests with shareholders.
• The Board is proactively adjusting executive compensation to remain competitive and attract/retain highly talented management, based on comparative market analyses.
• The company maintains robust corporate governance practices, including independent board committees (Audit, Compensation, Nominating and Corporate Governance) and a clear separation of CEO and Board Chairperson roles.

Negatives

• The company's net loss increased from $8.889 million in fiscal year 2023 to $9.541 million in fiscal year 2024, indicating a widening loss.
• The proposed executive compensation terms for the CEO, Chief of R&D, and CFO are deemed 'outside the range' of the company's current compensation policy, requiring special shareholder approval.
• The increase in the maximum annual value of equity awards for officers from 18x to 25x monthly base salary could lead to increased dilution.

Risks

• The company operates in a competitive labor market for highly talented Office Holders, necessitating competitive compensation packages for retention and recruitment.
• Failure to approve the proposed executive compensation terms and the amended compensation policy could hinder the company's ability to attract and retain key management personnel.
• The company's financial performance, particularly the increasing net loss, poses a risk to sustained operations and future profitability, requiring careful cash management.
• Reliance on equity-based compensation means that the actual value realized by executives is directly tied to share price performance, which is subject to market volatility and company-specific factors.

Future Outlook

The document primarily focuses on corporate governance and executive compensation for the upcoming annual meeting. It indicates a strategic intent to align executive compensation with market standards to attract and retain highly qualified management, which is crucial for the company's continued growth and success. The proposed compensation policy aims to be effective for the next three years, supporting long-term performance incentives.

Management Comments

• The Board believes that separation of the positions of Chairperson of the Board and Chief Executive Officer reinforces the independence of the Board in its oversight of our business and affairs.
• The Board believes that Ms. Taitel possesses the experience, skills, and qualities to fully perform her duty as a director and contribute to our success.
• The 2025 comparative executive compensation benchmark analysis found that the compensation terms, especially current annual salary of $419,000 of our CEO are materially below that of similar companies within the market. The update in compensation terms is therefore critical to provide an effective retention incentive.
• A significant portion of the CEOs total compensation is at-risk in the form of equity compensation and is directly tied to the Companys share performance. As a result, this component of compensation aligns the CEOs interests with those of shareholders by linking potential rewards to long-term stock price appreciation.

Industry Context

Entera Bio Ltd. operates in the biotech, pharmaceutical, and drug development sectors, which are characterized by intense competition for highly skilled talent. The company's proactive adjustment of executive compensation and its compensation policy, based on comparative benchmark analyses against peer-group companies in Israel and the United States, reflects the industry's need to offer competitive packages to attract and retain top-tier management. The emphasis on equity-based compensation aligns with common industry practices to incentivize long-term performance and shareholder value creation in R&D-intensive companies.

Comparison to Industry Standards

• The company's executive compensation terms, particularly current annual salaries, were found to be 'materially below' those of similar companies within the biotech, pharmaceutical, and drug development market, according to a 2025 comparative executive compensation benchmark analysis.
• The benchmark analysis included comparative data from peer-group companies in Israel and the United States, specifically those traded on NASDAQ or NYSE, and of similar size based on market capitalization, shareholder equity, balance sheet, sales turnover, operating profit, and/or net profit.
• The proposed amendments to the compensation policy, including increasing the maximum annual value of equity awards to 25 times monthly base salary, are intended to align the company's compensation framework with these comparable market standards.
• The company's practice of linking a significant portion of executive compensation to equity performance through options and RSUs is consistent with industry standards for aligning management incentives with long-term shareholder interests in the biotech sector.

Management Changes

Corporate Governance

Related Party Transactions

• The document details proposed compensation terms for the CEO, Chief of R&D, and CFO, which are considered related party transactions under Israeli Companies Law and require specific approvals due to personal interest.

Stakeholder Impact

• Shareholders: Direct impact through voting on executive compensation, director election, and compensation policy amendments, which affect potential dilution and long-term value alignment. Significant TSR increase in 2024 is positive for shareholders.
• Executives/Management: Direct impact from proposed salary increases, option grants, and RSU awards, designed to enhance retention and motivation.
• Employees: The compensation policy considers the ratio between Office Holders' compensation and other employees' salaries, aiming to preserve reasonable gaps and positive work relationships.
• Auditors: Kesselman & Kesselman (PwC) is proposed for re-appointment, ensuring continuity in financial oversight.

Next Steps

• Shareholders will vote on the election of Ms. Haya Taitel as a Class II director at the Annual Meeting on July 16, 2025.
• Shareholders will vote on the ratification and approval of revised compensation terms for CEO Miranda Toledano, Chief of R&D Dr. Gregory Burshtein, and CFO Dana Yaacov-Garbeli at the Annual Meeting.
• Shareholders will vote on the ratification and approval of the amended and restated compensation policy for directors and officers at the Annual Meeting.
• Shareholders will cast an advisory, non-binding vote on the compensation of named executive officers at the Annual Meeting.
• Shareholders will vote on the ratification and approval of Kesselman & Kesselman (PwC) as the independent auditors for fiscal year ending December 31, 2025, at the Annual Meeting.
• The company will announce the voting results for the proposals at the Annual Meeting and publish final detailed voting results in a Current Report on Form 8-K within four business days following the meeting.

Key Dates

Keywords

SEC filing, Proxy Statement, Executive Compensation, Corporate Governance, Shareholder Meeting, Total Shareholder Return, Net Loss, Equity Awards, Options, RSUs, Compensation Policy, Board of Directors, Audit Committee, Compensation Committee, Biotech, Pharmaceutical, Drug Development, Nasdaq